FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company ...
Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies. While advances in ...
UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 ...
Integrated operating frameworks are displacing fragmented vendor ecosystems, enabling faster launch readiness, omnichannel ...
DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...
Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...
At Gifthealth, Jeremy oversees all commercial strategy, new business development, and marketing functions.
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
Rare Pediatric Disease PRVs can accelerate FDA review timelines for another asset, and their resale market creates a tangible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results